Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

<jats:title>Key Points</jats:title> <jats:p>Lenalidomide penetrates ventricular CSF and is active as monotherapy in relapsed CNS lymphomas. Maintenance lenalidomide is feasible and may potentiate response duration after salvage in relapsed PCNSL and delay WBRT.</jats:p>

Original publication

DOI

10.1182/bloodadvances.2017014845

Type

Journal article

Journal

Blood Advances

Publisher

American Society of Hematology

Publication Date

10/07/2018

Volume

2

Pages

1595 - 1607